https://geovax.com/geovax-announces-issuance-of-malaria-vaccine-patent-2/2026-07-24T06:03:13-04:00https://geovax.com/geovax-announces-gedeptin-patient-enrollment-closure-for-phase-1-2-clinical-trial-among-advanced-head-and-neck-cancer-patients/2026-07-24T06:02:57-04:00https://geovax.com/geovax-appoints-dr-marc-pipas-as-executive-medical-director-oncology/2026-07-24T06:04:07-04:00https://geovax.com/geovax-announces-1-for-15-reverse-stock-split-to-regain-compliance-with-nasdaq-minimum-bid-requirement/2026-07-24T06:05:08-04:00https://geovax.com/geovax-reports-positive-interim-data-from-phase-2-clinical-trial-of-geo-cm04s1-as-a-universal-covid-19-vaccine-booster/2026-07-24T06:05:55-04:00https://geovax.com/geovax-announces-multiple-patent-issuances-and-allowances/2026-07-24T06:06:33-04:00https://geovax.com/geovax-to-present-at-the-2024-bio-ceo-investor-conference/2026-07-24T06:07:25-04:00https://geovax.com/geovax-to-report-2023-financial-results-and-provide-corporate-update-on-february-29-2024/2026-07-24T06:08:16-04:00https://geovax.com/geovax-reports-2023-year-end-financial-results-and-provides-business-update/2026-07-24T06:08:57-04:00https://geovax.com/geovax-achieves-milestone-in-transition-to-commercially-validated-manufacturing-system/2026-07-24T06:09:41-04:00https://geovax.com/geovax-to-present-at-the-36th-annual-roth-conference/2026-07-24T06:10:12-04:00https://geovax.com/geovax-to-present-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine-at-the-world-vaccine-congress/2026-07-24T06:10:49-04:00https://geovax.com/geovax-presents-data-on-geo-cm04s1-a-next-generation-covid-19-vaccine/2026-07-24T06:11:20-04:00https://geovax.com/geovax-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-may-14-2024/2026-07-24T06:11:54-04:00https://geovax.com/geovax-reports-first-quarter-2024-financial-results-and-provides-business-update/2026-07-24T06:13:11-04:00https://geovax.com/geovax-to-raise-approximately-1-3-million-of-gross-proceeds-in-offering-priced-at-the-market/2026-07-24T06:13:42-04:00https://geovax.com/geovax-to-present-at-bio-international-convention-2024/2026-07-24T06:14:13-04:00https://geovax.com/geovax-receives-barda-project-nextgen-award-to-conduct-phase-2b-clinical-study-evaluating-the-companys-next-generation-covid-19-vaccine-candidate-geo-cm04s1/2026-07-24T06:14:51-04:00https://geovax.com/geovax-partners-with-allucent-to-conduct-phase-2b-clinical-study-of-next-generation-covid-19-vaccine-candidate-with-funding-from-barda/2026-07-24T06:15:35-04:00https://geovax.com/geovax-provides-first-half-2024-business-update/2026-07-24T06:16:10-04:00https://geovax.com/geovax-to-raise-approximately-3-1-million-of-gross-proceeds-in-offering-priced-at-the-market/2026-07-24T06:16:37-04:00https://geovax.com/geovax-to-present-at-the-emerging-growth-conference-on-july-18-2024/2026-07-24T06:17:25-04:00https://geovax.com/geovax-to-report-second-quarter-2024-financial-results-and-provide-corporate-update-on-august-6-2024/2026-07-24T06:18:24-04:00https://geovax.com/geovax-announces-phase-2-plans-for-gedeptin-cancer-therapy-following-clinical-advisory-committee-review/2026-07-24T06:18:54-04:00https://geovax.com/geovax-reports-second-quarter-2024-financial-results-and-provides-business-update/2026-07-24T06:19:46-04:00https://geovax.com/geovax-appoints-teresa-lambe-acclaimed-professor-of-vaccinology-and-immunology-at-the-oxford-vaccine-group-to-its-scientific-advisory-board/2026-07-24T06:20:21-04:00https://geovax.com/geovax-to-present-at-the-emerging-growth-conference-on-august-21-2024/2026-07-24T06:20:49-04:00https://geovax.com/geovax-to-raise-approximately-8-5-million-of-gross-proceeds-in-offering-priced-above-the-market/2026-07-24T06:21:20-04:00https://geovax.com/registration-is-now-open-for-tribe-publics-webinar-event-now-is-not-the-time-to-monkeypox-around-featuring-geovax-labs-ceo/2026-07-24T06:21:52-04:00https://geovax.com/geovax-to-raise-approximately-5-0-million-of-gross-proceeds-in-offering-priced-at-the-market/2026-07-24T06:22:24-04:00https://geovax.com/geovax-to-participate-in-upcoming-investor-conferences-in-september/2026-07-24T06:22:53-04:00https://geovax.com/geovax-to-participate-in-the-3rd-annual-roth-healthcare-opportunities-conference/2026-07-24T06:23:23-04:00https://geovax.com/geovax-to-report-third-quarter-2024-financial-results-and-provide-corporate-update-on-november-12-2024/2026-07-24T06:23:54-04:00https://geovax.com/geovax-reports-third-quarter-2024-financial-results-and-provides-business-update/2026-07-24T06:24:35-04:00https://geovax.com/geovax-announces-positive-interim-data-review-for-phase-2-clinical-trial-of-covid-19-vaccine-booster-in-patients-with-chronic-lymphocytic-leukemia/2026-07-24T06:25:04-04:00https://geovax.com/geovax-to-present-at-the-noble-capital-markets-twentieth-annual-emerging-growth-equity-conference/2026-07-24T06:25:29-04:00https://geovax.com/geovax-receives-notice-of-allowance-for-cancer-vaccine-patent/2026-07-24T06:26:06-04:00https://geovax.com/geovax-to-review-2024-progress-at-biotech-showcase-during-j-p-morgan-healthcare-week-2025/2026-07-24T06:27:19-04:00https://geovax.com/geovax-to-review-2024-progress-at-the-emerging-growth-conference-on-january-16-2025/2026-07-24T06:28:08-04:00https://geovax.com/geovax-achieves-significant-progress-in-next-generation-covid-19-vaccine-development-throughout-2024/2026-07-24T06:28:38-04:00https://geovax.com/geovax-announces-major-gedeptin-milestone-with-plans-of-phase-2-trial/2026-07-24T06:29:11-04:00https://geovax.com/geovax-advanced-mva-manufacturing-process-aimed-to-enhance-vaccine-supply-worldwide/2026-07-24T06:29:46-04:00https://geovax.com/strengthening-americas-biosecurity-geovax-advances-domestic-vaccine-capability/2026-07-24T06:30:18-04:00https://geovax.com/geovax-announces-strategic-integration-of-ai-in-support-of-president-trumps-stargate-initiative/2026-07-24T06:30:59-04:00https://geovax.com/geovax-to-showcase-advancements-in-vaccines-immunotherapies-at-the-2025-bio-ceo-investor-conference/2026-07-24T06:31:37-04:00https://geovax.com/geovax-anticipates-significant-2025-progress-with-catalyst-rich-milestones-across-key-programs/2026-07-24T06:32:12-04:00https://geovax.com/geovax-congratulates-dr-valerie-montgomery-rice-on-receiving-the-2025-healthcare-champions-lifetime-achievement-award/2026-07-24T06:32:48-04:00https://geovax.com/geovax-to-present-at-the-emerging-growth-conference-on-february-19-2025/2026-07-24T06:33:25-04:00https://geovax.com/geovax-pledges-continued-support-for-vaccine-innovation-transparency-and-public-health/2026-07-24T06:40:34-04:00https://geovax.com/mpox-clade-1-in-the-u-s-highlights-the-need-for-vaccine-supply-diversification/2026-07-24T06:36:20-04:00https://geovax.com/geovax-highlights-the-role-of-mva-based-vaccines-in-advancing-public-health-preparedness/2026-07-24T06:37:02-04:00https://geovax.com/geovax-response-to-whos-third-declaration-of-mpox-as-a-public-health-emergency-of-international-concern/2026-07-24T06:37:38-04:00https://geovax.com/geovax-highlights-the-critical-role-of-mva-based-vaccines-in-u-s-biodefense-strategy/2026-07-24T06:38:20-04:00https://geovax.com/registration-is-now-open-for-tribe-publics-ceo-presentation-and-qa-webinar-event-mpox-2025-navigating-the-global-public-health-emergency-featuring-geovax-ceo-on-march-6-2/2026-07-24T06:40:47-04:00https://geovax.com/geovax-to-present-at-the-37th-annual-roth-conference/2026-07-24T06:42:17-04:00https://geovax.com/geovax-establishing-strategic-presence-in-europe-with-initial-footprint-in-the-uk/2026-07-24T06:43:13-04:00https://geovax.com/geovax-to-report-fourth-quarter-and-full-year-2024-financial-results-and-provide-corporate-update-on-march-27-2025/2026-07-24T06:43:54-04:00https://geovax.com/geovax-labs-announces-4-5-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/2026-07-24T06:44:31-04:00https://geovax.com/geovax-reports-2024-year-end-financial-results-and-provides-business-update/2026-07-24T06:45:49-04:00https://geovax.com/geovax-receives-uspto-notice-of-allowance-for-marburg-hemorrhagic-fever-vaccine-patent/2026-07-24T06:46:46-04:00https://geovax.com/geovax-to-present-clinical-data-at-upcoming-april-industry-events/2026-07-24T06:47:37-04:00https://geovax.com/geovax-to-present-at-the-emerging-growth-conference-on-april-16-2025/2026-07-24T06:48:15-04:00https://geovax.com/geovax-provides-update-on-barda-project-nextgen-and-outlines-2025-business-momentum/2026-07-24T06:48:50-04:00https://geovax.com/geovax-highlights-new-study-demonstrating-the-strength-of-multi-antigen-covid-19-vaccine-candidates/2026-07-24T06:49:47-04:00https://geovax.com/geovax-appoints-dr-senthil-ranganathan-as-vice-president-technical-development-and-cmc-operations/2026-07-24T06:50:22-04:00https://geovax.com/geovax-to-report-first-quarter-2025-financial-results-and-provide-corporate-update-on-may-1-2025/2026-07-24T06:51:01-04:00https://geovax.com/geovax-highlights-strong-clinical-results-following-presentation-of-multi-antigen-covid-19-vaccine-at-the-25th-annual-world-vaccine-congress/2026-07-24T06:51:31-04:00https://geovax.com/geovax-responds-to-detection-of-clade-i-mpox-in-north-carolina-wastewater/2026-07-24T06:52:03-04:00https://geovax.com/geovax-presents-gedeptinr-clinical-data-at-the-american-association-for-cancer-research-annual-meeting/2026-07-24T06:52:31-04:00https://geovax.com/geovax-reports-first-quarter-2025-financial-results-and-provides-business-update/2026-07-24T06:53:19-04:00https://geovax.com/geovax-applauds-white-house-executive-order-supporting-u-s-pharmaceutical-manufacturing-highlights-progress-in-domestic-mva-vaccine-production/2026-07-24T06:53:49-04:00https://geovax.com/geovax-expands-gedeptinr-patent-portfolio/2026-07-24T06:54:17-04:00https://geovax.com/geovax-highlights-dual-protective-potential-of-geo-cm04s1-following-presentation-at-the-aai-annual-meeting-2025/2026-07-24T06:54:45-04:00https://geovax.com/geovax-reaffirms-urgent-need-for-multi-antigen-covid-19-vaccines-as-cdc-shifts-recommendations/2026-07-24T06:55:24-04:00https://geovax.com/geovax-applauds-equip-a-pharma-initiative-reinforces-commitment-to-domestic-vaccine-manufacturing-and-biodefense-innovation/2026-07-24T06:55:59-04:00https://geovax.com/geovax-commends-fdas-shift-to-risk-based-covid-19-vaccination-guidance/2026-07-24T06:56:27-04:00https://geovax.com/geovax-congratulates-bipartisan-senate-action-to-onshore-critical-medical-manufacturing/2026-07-24T06:56:56-04:00https://geovax.com/geovax-to-showcase-innovative-covid-19-vaccine-data-at-the-keystone-symposia-on-vaccinology/2026-07-24T07:03:18-04:00https://geovax.com/geovax-highlights-broad-cross-protective-immunity-of-multi-antigen-covid-19-vaccine-candidates-at-keystone-symposia/2026-07-24T07:03:53-04:00https://geovax.com/geovax-announces-upcoming-presentation-at-the-european-hematology-association-2025-congress-highlighting-positive-immune-response-data-for-geo-cm04s1-in-cll-patients/2026-07-24T07:04:22-04:00https://geovax.com/geovax-responds-to-whos-fourth-declaration-of-mpox-as-a-global-public-health-emergency/2026-07-24T07:05:40-04:00https://geovax.com/geovax-to-participate-in-bio-international-convention-2025/2026-07-24T07:06:09-04:00https://geovax.com/geovax-receives-favorable-european-regulatory-guidance-supporting-streamlined-development-pathway-for-geo-mva/2026-07-24T07:06:40-04:00https://geovax.com/geovax-highlights-positive-immune-response-results-from-geo-cm04s1-in-cll-patients-at-the-european-hematology-association-2025-meeting/2026-07-24T07:07:10-04:00https://geovax.com/geovax-comments-on-fda-approval-of-keytruda-in-head-and-neck-cancer-underscoring-potential-for-gedeptin-combination-therapy/2026-07-24T07:08:08-04:00https://geovax.com/geovax-announces-issuance-of-patent-covering-novel-vaccine-construct-for-preventing-malaria-infection/2026-07-24T07:08:42-04:00https://geovax.com/geovax-to-raise-approximately-6-million-of-gross-proceeds-in-public-offering/2026-07-24T07:10:01-04:00https://geovax.com/geovax-responds-to-growing-mpox-threat-with-expedited-eu-pathway-and-platform-aligned-to-u-s-biodefense-objectives/2026-07-24T07:10:32-04:00https://geovax.com/geovax-highlights-critical-role-of-multi-antigen-covid-19-vaccines-as-nimbus-variant-underscores-persistent-and-evolving-public-health-threat/2026-07-24T07:11:00-04:00https://geovax.com/geovax-to-present-at-the-emerging-growth-conference-on-july-16-2025/2026-07-24T07:11:26-04:00https://geovax.com/geovax-highlights-growing-urgency-for-diversified-mpox-vaccine-supply-as-global-outbreaks-expand/2026-07-24T07:11:58-04:00https://geovax.com/geovax-highlights-ema-regulatory-milestone-as-catalyst-for-near-term-revenue-from-geo-mva-mpox-vaccine/2026-07-24T07:12:28-04:00https://geovax.com/geovax-to-report-second-quarter-2025-financial-results-and-provide-corporate-update-on-july-28-2025/2026-07-24T07:12:55-04:00https://geovax.com/geovax-to-advance-gedeptinr-into-first-line-therapy-neoadjuvant-combination-trial-following-landmark-keynote-689-results/2026-07-24T07:13:25-04:00https://geovax.com/geovax-announces-research-program-to-evaluate-needle-free-self-administered-geo-mva-vaccine-using-vaxxas-microarray-patch-technology/2026-07-24T07:14:40-04:00https://geovax.com/geovax-reports-second-quarter-2025-financial-results-and-provides-business-update/2026-07-24T07:15:22-04:00https://geovax.com/geovax-accelerates-development-of-geo-mva-vaccine-amid-expanding-global-mpox-crisis-and-reaffirmed-who-emergency-designation/2026-07-24T07:15:48-04:00https://geovax.com/geovax-urges-immediate-action-on-pandemic-preparedness-as-biodefense-gaps-expose-fragile-supply-chains/2026-07-24T07:16:23-04:00https://geovax.com/geovax-comments-on-hhs-mrna-vaccine-rollback-urges-full-embrace-of-mva-based-multi-antigen-vaccine/2026-07-24T07:17:05-04:00https://geovax.com/geovax-to-present-at-the-emerging-growth-conference-on-august-20-2025/2026-07-24T07:17:38-04:00https://geovax.com/geovax-announces-allowance-of-patent-protecting-multi-antigen-covid-19-vaccine-constructs/2026-07-24T07:18:08-04:00https://geovax.com/geovax-to-present-at-the-h-c-wainwright-27th-annual-global-investment-conference/2026-07-24T07:19:03-04:00https://geovax.com/geovax-to-present-multi-antigen-covid-19-vaccine-clinical-data-at-september-international-scientific-conferences/2026-07-24T07:19:33-04:00https://geovax.com/geovax-showcases-promising-geo-cm04s1-clinical-data-at-the-european-society-of-clinical-microbiology-and-infectious-disease-escmid-conference/2026-07-24T07:20:18-04:00https://geovax.com/geovax-showcases-positive-phase-2-data-for-geo-cm04s1-in-cll-patients-at-the-international-workshop-on-chronic-lymphocytic-leukemia-iwcll-conference/2026-07-24T07:20:47-04:00https://geovax.com/geovax-to-present-cm04s1-clinical-progress-at-the-emerging-growth-conference/2026-07-24T07:21:13-04:00https://geovax.com/geovax-reaffirms-commitment-to-evidence-based-vaccine-safety-and-development-of-geo-cm04s1-for-vulnerable-populations/2026-07-24T07:21:45-04:00https://geovax.com/geovax-expands-gedeptinr-development-to-additional-solid-tumor-indications/2026-07-24T07:22:32-04:00https://geovax.com/geovax-comments-on-u-s-america-first-global-health-strategy-and-highlights-companys-role-in-advancing-american-innovation-pandemic-preparedness-and-global-health-security/2026-07-24T07:23:03-04:00https://geovax.com/geovax-labs-announces-2-5-million-registered-direct-offering/2026-07-24T07:23:37-04:00https://geovax.com/geovax-to-sponsor-the-2025-dr-david-satcher-global-health-equity-summit/2026-07-24T07:25:16-04:00https://geovax.com/geovax-to-participate-in-the-4th-annual-roth-healthcare-opportunities-conference/2026-07-24T07:25:46-04:00https://geovax.com/geovax-to-present-covid-19-vaccine-data-at-world-vaccine-congress-europe-2025/2026-07-24T07:26:11-04:00https://geovax.com/geovax-leadership-to-participate-in-key-european-meetings-to-advance-partnering-discussions/2026-07-24T07:26:40-04:00https://geovax.com/geovax-highlights-positive-interim-results-for-multi-antigen-covid-19-vaccine-in-immunocompromised-patients-at-world-vaccine-congress-europe-2025/2026-07-24T07:27:05-04:00https://geovax.com/geovax-highlights-urgent-need-for-multisource-mpox-vaccine-supply-following-california-clade-1-cases/2026-07-24T07:27:38-04:00https://geovax.com/geovax-welcomes-new-idsa-guidance-highlighting-need-for-tailored-covid-19-vaccines-for-immunocompromised-patients/2026-07-24T07:28:09-04:00https://geovax.com/geovax-connects-idsa-guidance-on-covid-19-vaccination-for-immunocompromised-patients-with-recent-clinical-data-for-geo-cm04s1/2026-07-24T07:28:40-04:00https://geovax.com/bio-ceo-warns-u-s-could-lose-biotech-leadership-within-two-years-geovax-calls-on-congress-and-administration-to-act-now/2026-07-24T07:29:12-04:00https://geovax.com/geovax-announces-relocation-of-corporate-headquarters-and-laboratory-operations-to-support-accelerated-growth-and-pipeline-advancement/2026-07-24T07:29:58-04:00https://geovax.com/geovax-to-report-third-quarter-2025-financial-results-and-provide-corporate-update-on-november-13-2025/2026-07-24T07:30:25-04:00https://geovax.com/geovax-recognizes-world-immunization-day-advancing-innovation-and-trust-in-vaccination/2026-07-24T07:30:56-04:00https://geovax.com/geovax-reports-third-quarter-2025-financial-results-and-provides-business-update/2026-07-24T07:31:33-04:00https://geovax.com/geovax-to-present-at-the-noble-capital-markets-twenty-first-annual-emerging-growth-equity-conference/2026-07-24T07:32:02-04:00https://geovax.com/geovax-announces-jco-oncology-advances-publication-highlighting-favorable-safety-and-evidence-of-disease-stability-of-gedeptin-in-recurrent-head-neck-cancer/2026-07-24T07:34:05-04:00https://geovax.com/geovax-announces-issuance-of-u-s-patent-covering-enhanced-therapeutic-use-of-gedeptin-gene-therapy/2026-07-24T07:34:49-04:00https://geovax.com/geovax-announces-addition-of-renowned-global-experts-to-its-scientific-advisory-board/2026-07-24T07:35:17-04:00https://geovax.com/geovax-addresses-identification-of-new-mpox-variant/2026-07-24T07:35:47-04:00https://geovax.com/geovax-announces-british-journal-of-haematology-publication-highlighting-superior-t-cell-responses-of-geo-cm04s1-in-cll-patients/2026-07-24T07:36:16-04:00https://geovax.com/geovax-receives-u-s-patent-office-notice-of-allowance-for-broad-spectrum-covid-19-vaccine-design/2026-07-24T07:36:45-04:00https://geovax.com/geovax-announces-completion-of-geo-mva-fill-finish-supporting-phase-3-immunobridging-clinical-trial-start-up-in-early-2026/2026-07-24T07:37:20-04:00https://geovax.com/geovax-announces-publication-of-study-demonstrating-cross-variant-protection-using-the-multi-antigen-geo-cm04s1-vaccine/2026-07-24T07:37:52-04:00https://geovax.com/geovax-receives-formal-ema-scientific-advice-supporting-pivotal-phase-3-immunobridging-trial-for-geo-mva/2026-07-24T07:38:24-04:00https://geovax.com/geovax-to-raise-approximately-3-2-million-of-gross-proceeds-in-public-offering/2026-07-24T07:38:56-04:00https://geovax.com/geovax-labs-inc-to-review-progress-and-strategic-priorities-during-biotech-showcase-2026-and-j-p-morgan-healthcare-conference-week/2026-07-24T07:39:31-04:00https://geovax.com/geovax-announces-1-for-25-reverse-stock-split-to-regain-compliance-with-nasdaq-minimum-bid-requirement/2026-07-24T07:39:57-04:00https://geovax.com/geovax-highlights-2026-as-a-pivotal-year-for-progress/2026-07-24T07:40:23-04:00https://geovax.com/geovax-labs-announces-1-million-registered-direct-offering-priced-at-the-market-under-nasdaq-rules/2026-07-24T07:41:06-04:00https://geovax.com/geovax-endorses-global-call-to-sustain-mpox-response-as-evidence-confirms-epidemic-is-far-from-over/2026-07-24T07:41:32-04:00https://geovax.com/geovax-secures-exclusive-license-for-gedeptin-immune-checkpoint-inhibitor-combination-technology/2026-07-24T07:41:58-04:00https://geovax.com/geovax-announces-oncology-advisory-board-to-advance-gedeptin-development-across-solid-tumors/2026-07-24T07:42:20-04:00https://geovax.com/geovax-initiates-outreach-regarding-future-procurement-of-geo-mva-mpox-smallpox-vaccine/2026-07-24T07:43:27-04:00https://geovax.com/geovax-announces-european-society-of-medicine-publication-highlighting-geo-cm04s1-as-a-next-generation-covid-19-vaccine-for-immunocompromised-patients/2026-07-24T07:43:56-04:00https://geovax.com/geovax-provides-update-on-geo-mva-program/2026-07-24T07:44:30-04:00https://geovax.com/geovax-announces-a-warrant-inducement-transaction/2026-07-24T07:44:58-04:00https://geovax.com/geovax-highlights-single-dose-mpox-vaccine-data-at-world-vaccine-congress-2026/2026-07-24T07:45:48-04:00https://geovax.com/geovax-positions-geo-mva-to-address-supply-constraints-in-global-mpox-and-smallpox-vaccine-market/2026-07-24T07:46:27-04:00https://geovax.com/geovax-reports-2025-year-end-financial-results-and-provides-business-update/2026-07-24T07:47:13-04:00https://geovax.com/geovax-highlights-gedeptin-as-a-potential-immune-sensitizing-platform-amid-rising-industry-investment-in-in-vivo-cancer-therapies/2026-07-24T07:47:45-04:00https://geovax.com/geovax-advances-gedeptin-toward-phase-2-initiation-and-strategic-partnership-opportunities/2026-07-24T07:48:22-04:00https://geovax.com/geovax-initiates-phase-3-execution-activities-for-geo-mva-under-ema-aligned-immunobridging-pathway/2026-07-24T07:51:09-04:00https://geovax.com/geovax-announces-a-warrant-inducement-transaction-2/2026-07-24T07:51:39-04:00https://geovax.com/geovax-highlights-emerging-role-of-gedeptin-in-combination-immunotherapy-strategies-targeting-immunologically-cold-tumors/2026-07-24T07:52:18-04:00https://geovax.com/geovax-reports-first-quarter-2026-financial-results-and-highlights-geo-mva-phase-3-trial-implementation-plans/2026-07-24T07:52:58-04:00https://geovax.com/geovax-announces-3-million-private-placement-financing-priced-at-the-market-under-nasdaq-rules/2026-07-24T07:53:44-04:00https://geovax.com/geovax-highlights-strategic-importance-of-domestic-mva-based-preparedness-infrastructure-amid-escalating-global-infectious-disease-threats/2026-07-24T07:54:16-04:00https://geovax.com/geovax-comments-on-escalating-bundibugyo-ebola-outbreak-and-growing-need-for-flexible-biodefense-vaccine-platforms/2026-07-24T07:54:45-04:00https://geovax.com/geovax-accelerates-focus-on-geo-mva-commercialization-and-advancement-of-oncology-program-gedeptinr/2026-07-24T07:55:10-04:00https://geovax.com/registration-now-open-for-tribe-public-ceo-presentation-and-qa-webinar-event/2026-07-24T07:55:53-04:00https://geovax.com/geovax-ceo-welcomes-fifa-world-cup-2026-while-addressing-biothreat-readiness/2026-07-24T07:57:13-04:00https://geovax.com/geovax-ceo-highlights-renewed-strategic-interest-in-vaccine-platforms-and-infectious-disease-innovation/2026-07-24T07:57:48-04:00https://geovax.com/geovax-highlights-peer-reviewed-research-supporting-gedeptinr-potential-to-enhance-cancer-immunotherapy-responses/2026-07-24T07:58:50-04:00https://geovax.com/geovax-highlights-strategic-implications-of-recent-gedeptinr-findings-for-checkpoint-resistant-cancers/2026-07-24T07:59:26-04:00https://geovax.com/geovax-highlights-continued-u-s-government-investment-in-orthopox-preparedness-as-strategic-validation-of-long-term-vaccine-readiness/2026-07-24T08:00:08-04:00https://geovax.com/geovax-highlights-strategic-alignment-of-geo-mva-with-hhs-asprs-five-year-medical-countermeasure-preparedness-strategy/2026-07-24T08:00:41-04:00https://geovax.com/geovax-reports-second-quarter-2026-financial-results-and-provides-business-update/2026-08-13T11:46:28-04:00https://geovax.com/geovax-highlights-newly-published-independent-research-supporting-broader-filovirus-vaccine-strategies-and-strategic-value-of-its-mva-based-vaccine-portfolio/2026-08-13T11:50:37-04:00https://geovax.com/geovax-announces-completion-of-key-geo-mva-development-milestones-positioning-program-for-pivotal-phase-3-clinical-study/2026-08-13T11:52:21-04:00https://geovax.com/geovax-highlights-gedeptin%ef%b8%8f-tumor-priming-strategy-as-immuno-oncology-enters-new-phase/2026-08-17T16:13:41-04:00https://geovax.com/geovax-highlights-capabilities-amid-congos-expanding-ebola-outbreak/2026-08-17T18:05:22-04:00https://geovax.com/geovax-chairman-and-ceo-david-dodd-to-participate-in-2026-georgia-life-sciences-summit/2026-08-20T11:27:53-04:00